Effect Profile
CuratedModerate visuals with mild body load, low headspace
Tolerance & Pharmacokinetics
drugs.wikiTolerance Decay
Tolerance pattern is inferred from community cycles and MAOI-class experience; no formal human data. Anecdotally, consecutive heavy dosing for a week can blunt effects; spacing doses and cycling (≤14 days on, ≥14 off) is commonly used to mitigate this.
Cross-Tolerances
Harm Reduction
drugs.wiki• 9‑Me‑BC inhibits MAO-A (IC50 ≈1 µM) and MAO‑B (IC50 ≈15.5 µM) in vitro and upregulates neurotrophic factor genes (e.g., BDNF) in astrocytes; these properties likely underlie reported pro-motivational effects but also create MAOI‑type interaction risks. • Compared with irreversible MAOIs, reversible/weak MAO‑A inhibition confers a lower tyramine hazard, but large tyramine loads still reduce the safety margin; avoid oversized aged/fermented meals and be extra cautious if any other MAOI is on board. • MAOI coadministration with serotonergic drugs (e.g., SSRIs/SNRIs, MDMA, tramadol, dextromethorphan) can precipitate serotonin toxicity; do not combine and respect adequate washouts. • Combining with sympathomimetics (amphetamines, ephedrine/pseudoephedrine, phenylephrine) increases hypertensive crisis/arrhythmia risk; avoid. • In Parkinson’s regimens, adding MAO inhibitors to levodopa increases the chance of dyskinesias and insomnia; similar dopaminergic potentiation could occur if 9‑Me‑BC meaningfully inhibits MAO in vivo. • β‑Carbolines can act as photosensitizers that damage DNA under UVA; users frequently report photosensitivity/photophobia—minimize UV exposure, wear sunglasses/UPF clothing, and avoid tanning beds during cycles. • Oral and sublingual use are most common; sublingual solutions often sting and can numb taste—if irritation occurs, shorten contact time or switch to oral dosing. Intranasal use has frequent reports of painful irritation and is not advised. • Because some β‑carbolines can oxidize to permanently charged β‑carbolinium species with dopaminergic toxicity in experimental models, store 9‑Me‑BC away from light/heat, in airtight amber containers; avoid strong oxidizers. This is a theoretical quality-control precaution, not a documented 9‑Me‑BC clinical risk. • Expect insomnia and anxiety if taken late or at higher doses; dose in the morning, avoid caffeine late in the day, and consider non-sedating sleep hygiene first. Sexual side‑effects are reported anecdotally and are plausible by MAOI class effects. • Source quality varies; prefer suppliers providing third‑party analytics. Weigh accurately (milligram scale) or use volumetric solutions to avoid accidental high dosing and dust inhalation.
References
Drugs.wiki References
- 9‑Me‑BC inhibits MAO activity and stimulates neurotrophic factors (open‑access)
- 9‑Me‑BC inhibits MAO activity and stimulates neurotrophic factors (PubMed record)
- Exceptional properties of 9‑Me‑BC (dopaminergic stimulation/protection)
- 9‑Me‑BC cognitive enhancement in rats (10‑day regimen)
- MAO inhibitors – interactions, tyramine and serotonin syndrome (StatPearls)
- Tyramine interaction study with reversible vs irreversible MAOIs
- Selegiline + levodopa: dopamine‑related adverse effects/dyskinesia potentiation
- β‑Carbolines photosensitize DNA under UVA (mechanistic phototoxicity)
- β‑Carboline derivatives as DNA‑intercalating photosensitizers
- DAT‑mediated toxicity of β‑carbolinium derivatives (context for storage/oxidation caution)
- Bluelight community thread: subjective effects and use patterns
- Reddit r/Nootropics – sublingual/nasal irritation and ROA experiences
- Reddit r/Nootropics – photosensitivity/side-effect anecdotes